title: Combination anabolic and antiresorptive therapy for osteoporosis.
abstract: Osteoanabolic agents directly stimulate bone formation to improve bone mass and skeletal microarchitecture. At present, parathyroid hormone (PTH), in the form of the full-length molecule (PTH(1-84)) and its fully active, but truncated amino-terminal fragment, PTH(1-34) (teriparatide), are the only medications that belong to the osteoanabolic class. It is appealing to consider simultaneous combination therapy with antiresorptive and osteoanabolic drugs as potentially more beneficial than monotherapy with either class, given that their mechanisms of action differ. This review focuses on the research that has been conducted on combination therapy with PTH and an antiresorptive drug.
authors.affiliation: Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, PH 8W-864, New York, NY 10032, USA.
authors.forename: Natalie E
authors.initials: NE
authors.lastname: Cusano
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D045930:Anabolic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000378:metabolism
chemical_list: D045930:Anabolic Agents; D050071:Bone Density Conservation Agents